CO2023015286A2 - Un fab anti-tslp con estabilidad mejorada - Google Patents
Un fab anti-tslp con estabilidad mejoradaInfo
- Publication number
- CO2023015286A2 CO2023015286A2 CONC2023/0015286A CO2023015286A CO2023015286A2 CO 2023015286 A2 CO2023015286 A2 CO 2023015286A2 CO 2023015286 A CO2023015286 A CO 2023015286A CO 2023015286 A2 CO2023015286 A2 CO 2023015286A2
- Authority
- CO
- Colombia
- Prior art keywords
- fab
- improved stability
- tslp
- tslp fab
- nucleic acids
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 abstract 1
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente descripción se refiere a un Fab anti-TSLP con estabilidad mejorada, ácidos nucleicos que codifican dicho Fab, células hospedadoras y vector que comprende dichos ácidos nucleicos, y métodos para usar dicho Fab en el tratamiento de afecciones relacionadas con TSLP.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21169183 | 2021-04-19 | ||
| PCT/EP2022/060236 WO2022223514A1 (en) | 2021-04-19 | 2022-04-19 | An anti-tslp fab with improved stability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023015286A2 true CO2023015286A2 (es) | 2024-02-05 |
Family
ID=75588042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0015286A CO2023015286A2 (es) | 2021-04-19 | 2023-11-14 | Un fab anti-tslp con estabilidad mejorada |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4326767A1 (es) |
| JP (1) | JP2024516962A (es) |
| KR (1) | KR20230172508A (es) |
| CN (1) | CN117222665A (es) |
| AR (1) | AR125379A1 (es) |
| AU (1) | AU2022263281A1 (es) |
| BR (1) | BR112023021587A2 (es) |
| CA (1) | CA3216894A1 (es) |
| CL (1) | CL2023003082A1 (es) |
| CO (1) | CO2023015286A2 (es) |
| EC (1) | ECSP23086870A (es) |
| IL (1) | IL307651A (es) |
| TW (1) | TW202306982A (es) |
| WO (1) | WO2022223514A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306272C (zh) | 2000-11-17 | 2007-03-21 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法 |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
| CN113423733B (zh) * | 2019-09-04 | 2023-09-22 | 正大天晴药业集团股份有限公司 | 结合tslp的抗体及其用途 |
| BR112022008031A2 (pt) * | 2019-10-28 | 2022-07-12 | Medimmune Ltd | Formulações de pó seco de anticorpos de ligação à linfopoietina estromal tímica (tslp) e métodos de uso das mesmas |
-
2022
- 2022-04-19 BR BR112023021587A patent/BR112023021587A2/pt unknown
- 2022-04-19 TW TW111114769A patent/TW202306982A/zh unknown
- 2022-04-19 AR ARP220101003A patent/AR125379A1/es unknown
- 2022-04-19 KR KR1020237038201A patent/KR20230172508A/ko unknown
- 2022-04-19 CA CA3216894A patent/CA3216894A1/en active Pending
- 2022-04-19 IL IL307651A patent/IL307651A/en unknown
- 2022-04-19 AU AU2022263281A patent/AU2022263281A1/en active Pending
- 2022-04-19 JP JP2023563876A patent/JP2024516962A/ja active Pending
- 2022-04-19 EP EP22724429.0A patent/EP4326767A1/en active Pending
- 2022-04-19 CN CN202280029099.0A patent/CN117222665A/zh active Pending
- 2022-04-19 WO PCT/EP2022/060236 patent/WO2022223514A1/en active Application Filing
-
2023
- 2023-10-17 CL CL2023003082A patent/CL2023003082A1/es unknown
- 2023-11-14 CO CONC2023/0015286A patent/CO2023015286A2/es unknown
- 2023-11-16 EC ECSENADI202386870A patent/ECSP23086870A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23086870A (es) | 2023-12-29 |
| CN117222665A (zh) | 2023-12-12 |
| IL307651A (en) | 2023-12-01 |
| BR112023021587A2 (pt) | 2023-12-19 |
| EP4326767A1 (en) | 2024-02-28 |
| CA3216894A1 (en) | 2022-10-27 |
| CL2023003082A1 (es) | 2024-04-19 |
| WO2022223514A1 (en) | 2022-10-27 |
| KR20230172508A (ko) | 2023-12-22 |
| AU2022263281A9 (en) | 2023-11-16 |
| AU2022263281A1 (en) | 2023-11-09 |
| JP2024516962A (ja) | 2024-04-18 |
| AR125379A1 (es) | 2023-07-12 |
| TW202306982A (zh) | 2023-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011462A2 (es) | Tratamiento para el asma con anticuerpo anti-tslp | |
| PH12019501795A1 (en) | Method and apparatus for writing service data into block chain and method for determining service subset | |
| CO2017006651A2 (es) | Anticuerpos anti-c5 | |
| BR112019016462A2 (pt) | polipeptídeo modificado tendo atividade de citrato sintase, microrganismo do gênero corynebacterium e método para produzir um l-aminoácido | |
| CO2018007374A2 (es) | Anticuerpos anti-c5 y métodos de uso | |
| CR20190013A (es) | Anticuerpos anti-c5 y métodos de uso | |
| AR084377A1 (es) | Metodos y composiciones relacionados con enzimas de alcohol graso biosintetico | |
| AR100606A1 (es) | Variantes de lipasas y polinucleótidos que las codifican | |
| BR112019025744A8 (pt) | Método para aperfeiçoar a eficiência de transformação de planta e método para transformar planta | |
| CO2017011964A2 (es) | Un metodo para producir hcg recombinante | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| AR102919A1 (es) | Variantes de lipasa y polinucleótidos que las codifican | |
| BR112016013461A2 (pt) | microrganismo corineforme com uma capacidade melhorada para produzir l-lisina, e método para produzir l-lisina | |
| BR112017012885A2 (pt) | composição de meio e método para preparar toxina botulínica | |
| BR112016027341A2 (pt) | micro-organismo do gênero escherichia que tem um nível de atp intracelular aumentado e método para produzir l-aminoácidos | |
| BR112015016495A2 (pt) | composições, complexo de ácidos nucleicos e célula e meio não transitório legível por computador | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| ECSP23086870A (es) | Un fab anti-tslp con estabilidad mejorada | |
| BR112017012889A2 (pt) | composição de meio e método para preparar toxina botulínica | |
| BR112017012893A2 (pt) | composição de meio e método para preparar toxina botulínica | |
| BR112022007151A2 (pt) | Produção de bioproduto em uma célula hospedeira | |
| BR112018001855A2 (pt) | expressão de enzimas beta-xilosidase recombinantes | |
| AR098490A1 (es) | Mutantes del gen que codifica la enzima fenilacetona monooxigenasa (pamo) | |
| AR094105A1 (es) | Metodo para aumentar la resistencia a los patogenos en las plantas | |
| AR106259A1 (es) | Métodos de preservar la actividad biológica de los ácidos ribonucleicos |